

COURTESY COPY OF THE AMENDMENTS TO
THE CLAIMS UNDER ARTICLE 19

AMENDED CLAIMS

[received by the International Bureau on 12 March 2001 (12.03.01); PTO 28 JAN 2002
original claims 1-57 replaced by amended claims 1-53 (7 pages)]

1. The use of an effective amount of one or more catalysts which is/are enzyme(s) belonging to the heme biosynthetic pathway, or an enzymatically equivalent part or
5 analogue thereof, together with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treatment or prophylaxis of a disease caused by a deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway.
2. The use according to claim 1, wherein the disease is selected from the group consisting
10 of
acute intermittent porphyria (AIP),
ALA deficiency porphyria (ADP),
Porphyria cutanea tarda (PCT),
Hereditary coproporphyria (HCP),
15 Harderoporphyria (HDP),
Variegata porphyria (VP),
Congenital erythropoietic porphyria (CEP),
Erythropoietic protoporphyria (EPP), and
Hepatoerythropoietic porphyria (HEP).
20
3. The use according to claim 1, wherein the catalyst is one or more enzymes selected from the group consisting of
delta-aminolevulinic acid synthetase,
delta-aminolevulinic acid dehydratase (ALAD),
25 porphobilinogen deaminase (PBGD),
uroporphyrinogen III cosynthetase,
uroporphyrinogen decarboxylase,
coproporphyrinogen oxidase,
protoporphyrinogen oxidase, and
30 ferrochelatase,
or an enzymatically equivalent part or analogue thereof.
4. The use according to claim 1, wherein the disease is AIP and the enzyme is PBGD or
an enzymatically equivalent part or analogue thereof, preferably in combination with
35 ALAD.

14. The use according to claim 13, wherein the two compartment cartridge is combined with an injection device to administer the catalyst either by a needle or by a needle-less (high pressure) device.

5 15. The use according to any of the preceding claims, wherein the catalyst is formulated in a physiological buffer containing an enhancer for nasal administration.

16. The use according to claim 1, wherein the catalyst is formulated as an oral formulation containing lipid vesicles, such as those comprising phosphatidylcholine,
10 phosphatidylethanolamine, or sphingomyeline, or dextrane microspheres.

17. The use according to claim 1, wherein the catalyst is formulated so as to enhance the half-life thereof in the subject's bloodstream.

15 18. The use according to claim 17, wherein the catalyst has a polyethylene glycol coating.

19. The use according to claim 17, wherein the catalyst is complexed with a heavy metal.

20. The use according to claim 1, wherein the catalyst is an enzymatically equivalent part
20 or analogue of the enzyme and exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

21. The use according to claim 20, wherein the catalyst is a small artificial enzyme or an organic catalyst which can polymerise porphobilinogen to hydroxymethylbilane

25

22. The use according to claim 1, wherein the catalyst is said enzyme formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

30 23. The use according to claim 22, wherein the catalyst is tagged with specific carbohydrates or other liver cell specific structures for specific liver uptake.

24. The use according to claim 1, wherein the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.

35

33. The use according to claim 32 wherein the catalyst is recombinant human PBGD based on any of Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-erythro PBGD 1.1.1).

5

34. The use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form to prepare, either alone or in a combination with a suitable genetic vector and other components, a composition that can be used for gene therapy of a patient having a mutation in the PBGD gene causing an enzyme defect.

10

35. The use according to claim 34, wherein the enzyme deficiency is selected from enzyme deficiencies resulting in a disease selected from the group of Acute Intermittent Porphyria, (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).

15

36. The use according to claim 35 wherein the disease is Acute Intermittent Porphyria, (AIP).

20

37. The use according to claims 34-36, wherein the human PBGD cDNA sequence is selected from the group of Seq. ID NO 3 (clone PBGD 1.1) or Seq. ID NO 4 (non-erythro PBGD 1.1.1).

25 38. The use according to any of claims 34-37 wherein the said genetic vector is selected from the group of plasmids, adenovirus, retrovirus or associated adenovirus.

39. The use according to claims 34-38 wherein the application of said formulation results in substantially normal PBGD activity measured as a normalisation in urinary and/or

30 serum levels of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) compared to the levels before treatment or to a reduction in the frequency of attack of symptoms.

40. The use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form to prepare either alone or in a combination with a suitable genetic
35 vector and other components a composition facilitating the treatment of a patient with

expression plasmid pExp1-M2-BB to yield the final production strain PBGD which is free from production of PBGD of non human origin (Accession No 12915).

48. A method for the preparation of rhPBGD by a method comprising

5

a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding PBGD;

b) transforming a compatible host cell with the vector;

10 c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence;

d) recovering the expression product from the culture.

49. A method according to claim 48 further comprising a fermentation step.

15 50. A method according to claim 48 further comprising a purification step.

51. A method according to claim 50 wherein the purification is performed with a His-Tag (rhPBGD-His).

20 52. A rhPBGD having a stability of at least 6 weeks at 20°C, such as for at least 7 weeks, preferably for 8 weeks.

53. A rhPBGD having a stability resulting in a decrease in activity of less than 10% per month, such as less than 5%.

25